Successful Desensitization of a Patient with Rituximab Hypersensitivity
Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid d...
Saved in:
Main Authors: | Pinar Ataca, Erden Atilla, Resat Kendir, Sevim Bavbek, Muhit Ozcan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Case Reports in Immunology |
Online Access: | http://dx.doi.org/10.1155/2015/524507 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Desensitization of delayed-type hypersensitivity in mice: suppressive environment
by: Takashi Katsura, et al.
Published: (1993-01-01) -
Successful desensitization with 5-fluorouracil in a patient who developed anaphylaxis after 5-fluorouracil infusion
by: Mehmet Erdem Çakmak, et al.
Published: (2024-08-01) -
Lymphomatoid Granulomatosis Treated Successfully with Rituximab in a Renal Transplant Patient
by: Cindy Castrale, et al.
Published: (2011-01-01) -
Successful desensitization of donor-specific antibodies in a single cord blood transplant recipient
by: Mégane Tanguay, et al.
Published: (2025-12-01) -
Successful Outcome of a Corticodependent Henoch-Schönlein Purpura Adult with Rituximab
by: Taylor Pindi Sala, et al.
Published: (2014-01-01)